Investment Rating - The report does not explicitly state an investment rating for the herpes zoster vaccine industry Core Insights - The herpes zoster vaccine market in China is entering an accelerated cultivation phase due to the expansion of the aging population, increased awareness of pain and complications, and improvements in the adult immunization service system [2] - The demand for herpes zoster vaccines is primarily driven by the elderly and immunocompromised populations, with the market showing long-term growth potential due to demographic changes and rising chronic disease burdens [2][4] - The competitive landscape is shifting from a focus on product efficacy and safety to a comprehensive evaluation of commercialization capabilities, including channel coverage, organizational mobilization efficiency, and service operation capabilities [2][3] Summary by Sections Overview of Herpes Zoster Disease in China - Herpes zoster is a common infectious disease in adults, with incidence risk significantly increasing with age and declining immune function [13] - The disease burden is concentrated in the elderly and immunocompromised populations, with a notable impact on quality of life due to complications such as postherpetic neuralgia [13][14] Vaccination Coverage of Herpes Zoster Vaccines in China - As of September 2024, the vaccination rate for herpes zoster among individuals aged 60 and above in China is approximately 0.79%, indicating a very low penetration stage [15] - The vaccination rate for this demographic has increased from less than 0.1% in 2022 to an estimated 0.8% in 2024, with significant regional disparities [17][18] Technology Segmentation of Herpes Zoster Vaccines in China - The herpes zoster vaccines in China are categorized into three main technological routes: live attenuated vaccines, recombinant subunit vaccines, and self-replicating RNA vaccines [20] - The market is characterized by a diverse range of products, with different technologies offering unique advantages in terms of immunogenicity, safety, and cost [5][20] Policy Landscape of the Herpes Zoster Vaccine Industry in China - The regulatory framework for herpes zoster vaccines is based on non-mandatory adult vaccine supervision, promoting accessibility and penetration through local projects and payment tools [27] - Recent policies aim to enhance the quality and safety of vaccination services, standardizing processes and improving public trust in adult immunization [27] Value Chain and Supply System of Herpes Zoster Vaccines - The value chain includes upstream raw material supply, midstream vaccine production, and downstream vaccination services, with a focus on improving efficiency across the entire chain [30][33] - The domestic supply of key raw materials is increasing, with local manufacturers enhancing their capabilities and reducing costs, thereby improving the overall competitiveness of the industry [40][46] Future Growth Drivers of the Herpes Zoster Vaccine Industry - The growth of the herpes zoster vaccine market will be driven by the diversification of technological platforms, improving coverage and accessibility [29] - The industry's ability to convert low-penetration populations into new vaccination opportunities will be crucial for future growth [3]

Core Viewpoint - Hualan Biological's subsidiary has received approval for a clinical trial of a recombinant shingles vaccine, indicating a significant step in addressing the growing demand for shingles vaccination in China due to an aging population and increased health awareness [1] Company Summary - Hualan Biological's subsidiary, Hualan Biological Vaccine Co., Ltd., has been granted a Clinical Trial Approval Notice by the National Medical Products Administration for its recombinant shingles vaccine [1] - The vaccine utilizes a mature CHO cell platform to express key proteins of the varicella-zoster virus, aiming to induce immune responses to prevent shingles and its complications [1] - This product represents an important strategic move for Hualan in the shingles prevention sector, potentially offering a new preventive option for susceptible populations [1] Industry Summary - Shingles is caused by the reactivation of the varicella-zoster virus, primarily affecting middle-aged and elderly individuals, with symptoms worsening with age [1] - Currently, there are two marketed shingles vaccines in China, indicating a competitive landscape [1] - The demand for shingles vaccination is expected to grow significantly due to the accelerating aging process in the country and rising public health awareness, suggesting a promising market outlook for domestic shingles vaccines [1]